Recent Quotes (30 days)

You have no recent quotes
chg | %

Life Science Developments Ltd news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

LIFE 2.45 -0.30 (-10.91%)
price chart
What's in Life Science Developments Ltd After Today's Huge Increase?
The stock of Life Science Developments Ltd (LON:LIFE) is a huge mover today! The stock increased 27.62% or GBX 0.72 on June 21, hitting GBX 3.35.
Brexit spells upheaval for EU and UK drug regulation
The pharmaceuticals industry employs more than 70,000 people in the UK and accounts for 25 percent of all business research and development spending in the country. Many scientists are concerned that funding for academic research, which has been well ...
Cambridge leads fightback from Brexit carnage
Life science company AstraZeneca, which is relocating its corporate HQ to Cambridge and building R & D and genomics centres in the city with over 2,500 jobs, also defied the odds as its share price increased 35p to �3,934.00p.
Imperial institute at intersection of engineering and molecular science opens
A new institute at Imperial to fast-track the development of molecular engineering research officially launches today. The global challenges faced ... The Institute for Molecular Science and Engineering (IMSE) aims to accelerate the pace of development ...
Amgen sponsors the QB3@953 life sciences incubator
As part of the sponsorship, Amgen launched two “Amgen Golden Ticket” awards, providing each winner with one year of lab space at the QB3@953 life sciences incubator, additional facility benefits and connections to Amgen's scientific and business leaders.
DMU's global outlook wins Times Higher Education top prize
The team behind De Montfort University Leicester's (DMU) pioneering international experience programme are celebrating today after winning a prestigious national award.
Directors at North East life sciences firm upbeat despite 15% slump in sales
The developments triggered a decrease in the share price, which dropped by 24% from �2.95 on 31 March 2015 to �2.25 at the end of FY 2016 - a 52-week low.
Reactions to the EU Referendum
Steve Bates, Chief Executive of the UK BioIndustry Association (BIA), commented on the news: “This is not the outcome that the BIA wanted but we accept the views of the UK people.
Great Britain votes to separate from European Union  PharmaTimes
Scans show possible link between brain development and antisocial behaviour
When compared with brain scans from 25 healthy men of the same age, the scientists noticed clear differences. Those diagnosed with conduct disorder before the age of 10 had similar variations in the thickness of the brain's cortex.
Cardiff life sciences firm Verona Pharma raises �44.7m
Cardiff-based drug development firm Verona Pharma has received a huge boost in bringing its medicines to treat respiratory diseases to market after raising �44.7m.